A special commission in Germany has put forth proposals to cap the burgeoning costs associated with the country’s statutory health insurance system. This comes as Chancellor Friedrich Merz’s administration aims to implement tax and welfare reforms in the coming months to address a projected €15.3 billion shortfall without intervention.
In the pharmaceutical realm, Insilico Medicine and Eli Lilly are entering a $2.75 billion strategic partnership focused on AI-driven drug discovery. This move aligns with the growing trend of leveraging AI and advanced modelling tools to expedite research and development processes within the industry, in an effort to enhance efficiency.
On another note, Butterfly Network has secured regulatory clearance from the FDA for its AI-powered ultrasound tool designed to estimate gestational age, a development that promises to improve maternal care access in underserved regions. Furthermore, scrutiny surrounds Viridian Therapeutics’ recent trials for a thyroid eye disease drug, after it failed to meet investors’ expectations despite trial success.